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 Transforming growth factor beta (TGF-ß), a cytokine capable of altering cell 
growth and differentiation, as well as related transcription factors called SMADs, are 
among the proteins known to be modified by docosahexaenoic acid (DHA) treatment in 
T-cells. Unpublished data has indicated that these proteins may be modified by DHA in 
colon cancer cells. In the current project, a thorough investigation of the effects of DHA 
on TGF-ß and SMAD protein expression and activation in COLO205 and WiDr colon 
carcinomas, both of which show significant inhibition of cell proliferation upon DHA 
supplementation, will be examined using Western Blotting and ELISA. Overall, DHA 
does not appear to effect TGF-ß expression, but it may still play a role in down-regulating 




I would like to thank the members of my lab for their help and advice on this project and 
their patience with me: Dr. Ronald S. Pardini, Dr. Keith D. Kikawa, and Michael 
Mouradian. A significant portion of this project was funded by the General 
Undergraduate Research Award.  
iii 
 
Table of Contents 
 
Abstract…………………………………………………………………………………     i 
Acknowledgements…………………………………………………………………….     ii 
Table of Contents……………………………………………………………………….   iii 
Introduction……………………………………………………………………………..    1 
Methods…………………………………………………………………………………    4 
Fatty Acid Titration……………………………………………………………………..    7 
Effects of DHA on TGF-ß ……………………………………………………………...   9 
Knockdown of TGF-ß …………………………………………………………….........  10  
Fatty Acid Treatment Supplemented with TGF-ß siRNA……………...………………  12 
Western Blot Results of SMAD Proteins………………..……………...………………  14 
Discussion………………………………………………………………………………. 16 




 Unchecked cell growth is the essence of cancer. So much basic research has 
focused on how cancer cells escape normal growth controls. Scientists have turned their 
focus to a family of secreted growth regulatory proteins, known collectively as 
transforming growth factor-beta (TGF-ß), which are one of the few known classes of 
proteins that can inhibit cell growth.
1,2
 The TGF-ß system is a basic pathway that 
provides a simple route for signals to pass from the extracellular environment to the 
nucleus and controls a plethora of cellular responses and figures prominently in animal 
development. In its normal state, the TGF-ß pathway restricts cell growth, differentiation, 
and cell death. When a healthy cell becomes cancerous, various components of the TGF-
ß signaling pathway become mutated, which makes the newly cancerous cell resistant to 
the effects of normally functioning TGF-ß.
3,4
 These resistant cells then grow without 
regulation. Previous research has shown that in colon cancer, one third of tumors have 
mutated TGF-ß receptors, and the remainder of the tumors have mutations in the 




 Recent cellular, biochemical, and structural studies have revealed significant 
insight into the mechanisms of the activation of TGF-ß receptors through the activation 
of SMAD proteins through phosphorylation, the transcriptional regulation of target gene 
expression, and the control of SMAD protein activity and degradation.
6
 TGF-ß may 
induce apoptosis, programmed cell death, in numerous ways including the SMAD 
pathway.
6
 The SMAD pathway is the canonical signaling pathway that TGF-β family 
members signal through. In this pathway, TGF-β dimers bind to a type II receptor which 
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recruits and phosphorylates a type I receptor. The type I receptor then recruits and 
phosphorylates a receptor regulated SMAD (R-SMAD), which consists of SMAD2 and 
SMAD3. The R-SMAD then binds to SMAD4 and forms a heterodimeric complex. This 
complex then enters the cell nucleus where it acts as a transcription factor for various 
genes.
7 
Elements involved in cell proliferation regulation, which have been clearly shown 
to be controlled in part by TGF-ß, include: “the cyclin-associated proteins cyclin D1, 
cyclin-dependent kinase 4, p21, p27, p15, c-myc, Rb, p130, and p107.”
4
 In addition to the 
cyclin associated proteins, the extracellular matrix proteins and regulators of extracellular 
matrix proteins: fibronectin, tenascin, plasminogen activator inhibitor 1, and a variety of 
other genes that affect apoptosis, differentiation, and other cell behaviors, appear to be 
transcriptionally regulated by TGF-ß.
4
 
 Another pathway that parallels the TGF-β/SMAD pathway is the BMP (bone 
morphogenetic protein)/SMAD pathway. Like TGF-β, BMPs constitute a large family of 
signaling molecules that regulate a variety of important cellular processes including: 
“morphogenesis, cell-fate determination, proliferation, differentiation, and apoptosis.”
8
 
The receptor for BMP is a member of the TGF-β Ser/Thr kinase receptors. Therefore, 
binding a BMP ligand will induce multimerization, autophosphorylation, and activation 
of the receptor.
8
 The BMP receptor subsequently phosphorylates R-SMAD, which 
constitutes SMAD1, SMAD5, and SMAD8. These phosphorylated SMADs then dimerize 
with SMAD4 and translocates to the nucleus where they target a variety of DNA binding 
proteins. While TGF-β and BMP induce an independent set of SMAD proteins, both 
pathways eventually have their R-SMADs form a heteromeric complex with SMAD4 to 
stimulate transcription of target genes involved with proliferation.
8
 It is undoubtedly 
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possible that mutations anywhere along the SMAD pathway may lead to unchecked 
growth in cancer.  
In the current research, certain dietary fatty acid supplementations on cancer cells 
have been known to induce apoptosis. Specifically, docosahexaenoic acid (DHA), an 
omega-3 polyunsaturated fatty acid (PUFA), has demonstrated anti-cancer properties in 
numerous in vitro and in vivo models of cancer.
9
 Tumors enriched with long chained 
omega-3 polyunsaturated fatty acids, such as DHA, possess membranes with increased 
fluidity, an elevated unsaturation index, enhanced transport capabilities that results in 
accumulation of selective anti-cancer agents, increased activity of selected drug 
activating enzymes, and alteration of signaling pathways important for cancer 
progression.
7,10
 Studies have found that the effect of DHA on various cancer cell lines, 
including the human breast cancer cell line MDA-MB-231, show that DHA incorporation 
has: an anti-proliferative effect, induces apoptosis, and reduces the invasive potential of 
cancer cells.
9
 Past research has also determined that DHA can inhibit growth of human 
colon carcinoma cells, COLO205 and WiDr, both of which will be used in this study.
11
 
Provided that apoptosis can be affected by DHA, an investigation will be made to 
correlate its possible effect on the TGF-ß system and/or the BMP system as well as the 






WiDr cells were maintained in MEM Eagle (Mediatech, Inc., Herndon, VA) 
supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 1.5 g/L sodium 
bicarbonate, and 1.0 mM sodium pyruvate. COLO205 cells were maintained in RPMI 
1640 supplemented with 10% FBS, 1.5 g/L sodium bicarbonate, 0.15% D (+)glucose, 0.3 
mM sodium pyruvate, and 5.0 mM4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid 
mixture. Both cell lines were grown in flasks as monolayers at 37◦C in a saturated 
humidified environment consisting of 5% CO2.
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Fatty Acid Treatments 
Fatty acid methyl esters (LA and DHA) were purchased from Sigma (St. Louis, 
MO) and diluted in ethanol to a final concentration of 10 mg/mL stock solution. Fatty 
acid stock solutions were flushed with nitrogen gas and stored in the dark at –20◦C. 
Cultured cells were plated with approximately 50% confluency on a 96 well micropipette 
plate. Following 24 hour incubation, cells were treated with 125 μM LA and DHA 
respectively. Cells treated with ethanol were used as controls for each experiment. 
12
 
Cell Proliferation Assay 
 XTT Cell Proliferation Assay Kit was used to measure cell proliferation (Roche, 
Indianapolis, IN). The cells were plated in a 96-well format and treated with fatty acid 
and/or siRNA as described. After fatty acid treatment, the cells were incubated for 24- 48 
hours incubation at 37◦C in a saturated humidified environment consisting of 5% CO2. 
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At the end of incubation, XTT reagent was added 4-24 hours before the experiment end 
point and was read on a spectrophotometer at 450 nm with a reference point at 650 nm.  
TGF-ß siRNA Treatment 
 The cancer cells were transfected with siRNA using OptiMem following 
manufacture protocol 24 hours of incubation after cell culturing (Invitrogen, Carlsbad, 
CA). The cells were treated at a 5 nM concentration of siRNA using HiPerFect reagent 
following manufacture protocol (Qiagen, Valencia, Ca). If the experiment involved FA 
treatment, the cells were treated 24 hours after transfection with siRNA. 
TGF-ß ELISA Kit 
 Conditioned media was collected for analysis after 48 hour incubation of FA 
treated cells. TGF-ß levels were quantified using the TGF beta ELISA kit following 
manufacture protocol (eBioscience, San Diego, Ca). The plates were read on a 
spectrophotometer at 450 nm without a reference wavelength. 
Western Blot 
 Cells were washed with ice-cold PBS and lysed using GTP-lysis buffer [50 mM 
HEPES (pH 7.5), 15 mM NaCl, 6 mM sodium deoxycholate, 1% NP-40, 10% gylercol, 
10 mM MgCl2, 1 mM EDTA] containing freshly added protease and phosphatase 
inhibitors. Supernatants were analyzed for protein concentration using Bio-Rad’s DC 
assay (Hercules, CA). Samples were resolved by SDS-PAGE, transferred to a PVDF 
(Polyvinylidene Fluoride) membrane (Bio-Rad, Hercules, Ca), blocked in 5% milk 
protein with TBS-T (Tris Buffered Saline with 0.05% Tween), and probed with the 
appropriate primary antibody in 3% milk protein with TBS-T. Detection was performed 
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using HRP-conjugated secondary antibody and visualized with ECL reagent (GE 







 Previous data in the lab has shown that the cell proliferation of COLO205 and 
WiDr have a dosage response to DHA treatments. In order to determine an inhibitory 
working concentration of which 50% of the tissue cultures show inhibition of growth, 
IC50; both colon carcinoma cell lines were treated with varying concentrations of DHA, 






























Figure 1. Fatty Acid Titration on COLO205 
(n=3) COLO205 cells were plated on a 96-well plate format and treated with their 
respective FA concentrations. After 48 hour incubation, percent cell proliferation with 


































Figure 2. Fatty Acid Titration on WiDr 
(n=3) WiDr cells were plated on a 96-well plate format and treated with their respective 
FA concentrations. After 48 hour incubation, percent cell proliferation with respect to the 
ethanol (EtOH) control treatment was measured using the XTT assay kit. 
 
 The results of Figure 1 and Figure 2 showed with statistical significance that both 
colon carcinoma cell lines have a dosage response to FA treatment. With respect to LA, 
DHA was more effective in inhibiting cell growth. Overall it could be determined that 
both cell lines have a DHA IC50 concentration of around 100-150 μM. For future 
experiments involving DHA and LA treatment, both cell lines were treated at a 150 μM 
concentrations.  
 Knowing that DHA significantly inhibited cell growth, the next approach was to 
examine the mechanism of how it affects cell signaling. The signaling molecule, TGF-ß, 
is a cytokine found in the extracellular environment that is known to induce apoptosis. 






























Figure 3. Effects of DHA on TGF-ß levels 
(n=2) The conditioned media of both cell lines were analyzed 48 hours after FA 
treatment. TGF-ß levels were quantified using the TGF-ß ELISA kit. Unconditioned 
media controls were RPMI for COLO205 and MEM for WiDr. 
 
 According to Figure 3, TGF-ß levels did not appear to be significantly affected by 
DHA treatment on the cells. It is important to note that TGF-ß is present in the control 
unconditioned media possibly due to the fetal bovine serum ingredient. Variation could 
be seen in the figure so the experiment must be repeated to attain statistical significance. 
In addition, the amount of TGF-ß quantified must be normalized to cell count when this 
experiment will be repeated since it is important to account for the fewer number of cells 
producing TGF-ß in the DHA treatment group. 
 Although DHA did not appear to have any effect on the expression of TGF-ß, the 
next approach was to knock down the expression of TGF-ß, but still quantify any changes 
in expression in response to fatty acid treatment. The knockdown of this gene was 






























Figure 4. Knockdown of TGF-ß in COLO205 
(n=1) TGF-ß levels were quantified using the TGF-ß ELISA kit. Conditioned media was 
collected 48 hours after siRNA (2 nM) and FA treatment (125 uM).  Conditioned media 
for the pre-treatment group was collected 24 hours after treatment with siRNA, but prior 





























Figure 5. Knockdown of TGF-ß in WiDr 
(n=1) TGF-ß levels were quantified using the TGF-ß ELISA kit. Conditioned media was 
collected 48 hours after siRNA (2 nM) and FA treatment (125 uM).  Conditioned media 
for the pre-treatment group was collected 24 hours after treatment with siRNA, but prior 
to FA treatment. 
 
 According to Figure 4 and Figure 5, the knockdown of TGF-ß using siRNA was 
successful for both cell lines with respect to their control mock treatment and non-
silencing siRNA (ns-siRNA) treatment groups. In Figure 4, there appeared to be no effect 
of LA on TGF-ß levels with respect to the EtOH control. However, treatment with the 
DHA on COLO205 showed that TGF-ß levels decreased to the level of TGF-ß siRNA 
treatment in the pre-treatment group. On the other hand, this shows some discrepancy 
with respect to Figure 3, where the conclusion was drawn that DHA had no effect on 
TGF-ß levels with respect to the EtOH control. As for Figure 5, treatment of WiDr with 
EtOH, DHA, and LA appeared to have reduced overall expression of TGF-ß to the level 
of TGF-ß siRNA treatment in the pre-treatment group. Unlike COLO205, the WiDr cells 
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showed no significant change in TGF-ß expression between the DHA treatment and 
EtOH control group. A definitive conclusion cannot be drawn on these results so the 
experiments must be repeated. Similarly to Figure 3, the amount of TGF-ß quantified 
must be normalized to cell count for any definitive conclusions. Overall, these results 
indicated the effectiveness of treating the two cell lines with TGF-ß siRNA. 
 Although treatment of both cell lines with DHA did not appear to affect TGF-ß 
levels, cell proliferation was still measured to see if knockdown of this gene would have 

































Figure 6. Fatty Acid Treatment Supplemented with TGF-ß siRNA on COLO205 
(n=1) COLO205 cells were plated on a 96-well plate format and treated with FA (125 
uM) and/or siRNA (2 nM). After 48 hour incubation, percent cell proliferation with 



































Figure 7. Fatty Acid Treatment Supplemented with TGF-ß siRNA on WiDr 
(n=1) WiDr cells were plated on a 96-well plate format and treated with FA (125 uM) 
and/or siRNA (2 nM). After 48 hour incubation, percent cell proliferation with respect to 
the ethanol (EtOH) control treatment was measured using the XTT assay kit. 
 
 The results indicated that both cell lines had no significant inhibition of growth in 
response to the knockdown of the TGF-ß. However, the experiment needs to be repeated 
to attain statistical significance. 
 After determining that TGF-ß may not appear to significantly affect both the 
COLO205 and WiDr cancer cell lines, an investigation was directed at the intracellular 
SMAD pathway. The SMAD pathway is the canonical signaling pathway that TGF-β 
family members signal through. Unpublished data has shown that activated p-SMAD2 is 
down-regulated in response to DHA treatment. The activated and total SMAD2 protein 




Figure 8. Effects of FA treatment on SMAD2 Protein Activation and Expression  
Total cell lysates were collected from both cell lines 48 hours after FA treatment at their 
respective concentrations (125 uM). Supernatants were analyzed for protein 
concentration using the Bio-Rad’s DC assay. 50 ug of each protein sample was resolved 
by SDS-PAGE, transferred to a PVDF membrane, probed with the appropriate primary 
antibody and HRP-conjugated secondary antibody, and visualized with ECL reagent. 
 
Due to the high background signal that the pSMAD2 antibody had on the 
membrane, blotting for the p-SMAD2 protein was repeated multiple times. In the end, 
clear results could not be obtained so the experiment for Figure 8 was generously 
performed by Dr. Keith D. Kikawa. This figure showed pSMAD2 levels, with respect to 
total SMAD2 protein, in the TGF-ß/SMAD pathway was down-regulated in DHA treated 
WiDr cells and in both LA and DHA treated COLO205 cells. Although the blot did 
appear slightly dirty, a conclusion could be made that pSMAD2 levels appeared to be 




Figure 9. Effects of FA Treatment on Remaining SMAD Protein Activation and 
Expression 
Total cell lysates were collected from both cell lines 48 hours after FA treatment at their 
respective concentrations (125 uM). Supernatants were analyzed for protein 
concentration using the Bio-Rad’s DC assay. 50 ug of each protein sample was resolved 
by SDS-PAGE, transferred to a PVDF membrane, probed with the appropriate primary 
antibody and HRP-conjugated secondary antibody, and visualized with ECL reagent. 
 
In addition to the TGF-β signaling, the intracellular SMAD pathway can be 
induced by BMP, bone morphogenetic protein, signaling. For Figure 9, the blot clearly 
indicated a change in protein levels for pSMAD1/5 in response to DHA treatment. Even 
though the β-actin loading control was slightly uneven for the samples, densitometry 
results indicated down-regulation of pSMAD1/5 from the BMP/SMAD pathway in both 
colon carcinoma cell lines treated with DHA. Figure 9 also showed that SMAD4, which 
is the protein of intersection for the TGF-ß and BMP intracellular SMAD signaling 
pathway, was down-regulated in DHA treated WiDr cells and in both LA and DHA 
treated COLO205 cells. It is important to note that SMAD4 does exhibit a similar pattern 





 Overall, both the COLO205 and WiDr colon cancer cell lines showed significant 
inhibition of growth in response to DHA treatment in a dosage response manner 
according to Figure 1 and Figure 2. As a result, an investigation of the TGF-ß/SMAD 
signaling pathway was proposed as DHA’s mechanism of action because of their 
involvement in cellular proliferation and apoptosis. The extracellular signaling protein, 
TGF-ß, was analyzed first. TGF-ß levels did not appear to significantly change upon 
treatment of DHA with respect to the EtOH control for both cell lines in Figure 3. 
However, according to Figure 4, upon treatment of the cells with TGF-ß siRNA, DHA 
appeared to have downregulated the expression of TGF-ß in COLO205 cells. As for 
Figure 5, treatment of WiDr with EtOH, DHA, and LA appeared to have reduced overall 
expression of TGF-ß to the level of TGF-ß siRNA treatment in the pre-treatment group. 
There are definitely some data discrepancies, so these experiments will have to be 
repeated at a later date. Although the EtOH control group should inherently have no 
effect on TGF-ß levels, this could possibly be due to the confluency of the WiDr cells 
prior to treatment. High confluency of cells may permanently alter cellular signaling. 
Since these experiments have been replicated no more than once and the amount of TGF-
ß quantified needed to be normalized to cell count, no definitive conclusion can be made 
until the results are consistent and amount of cells secreting the cytokine protein is 
accounted for. 
After observing the effects that DHA had on TGF-ß levels, cell proliferation was 
measured to see if knockdown of TGF-ß would have any effect on the cells. According to 
Figure 6 and Figure 7, the results indicated that knockdown of TGF-ß did not appear to 
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affect cell proliferation, nor did it affect the typical response of the cells to the FA 
treatment. Even though the experiment will need to be repeated in the future, the 
conclusion could be made that TGF-ß may not necessarily be playing a role in cancer cell 
survivability. Since several documented papers have indicated that one third of cancer 
cell tumors have mutated TGF-ß receptors or SMAD proteins, it is quite possible that 
COLO205 and WiDr may constitute those tumor lines.
4,5
 Therefore, the SMAD proteins 
in the SMAD pathway were the likely candidates that may contribute to cancer cells 
bypassing normal cellular proliferation.  
After treating both cell lines with LA and DHA at their IC50 concentrations, their 
total protein was analyzed using Western Blotting. Figure 8 and Figure 9 revealed several 
important effects that DHA had on the SMAD signaling proteins. While WiDr had a 
down-regulation of pSMAD2 and SMAD4 in only the DHA treatment, COLO205 had a 
down-regulation for the same proteins in both the LA and DHA treatment. Although they 
are both colon cancer cell lines, they appear to have a slightly different response to fatty 
acid treatments. Further studies may need to be conducted, but it seems that the TGF-
β/SMAD pathway in COLO205 may be more sensitive to LA treatment than WiDr.  
Figure 8 and Figure 9 also looked at pSMAD1/5, which is a SMAD protein 
signaled through BMP signaling. Unlike pSMAD2 and SMAD4, pSMAD1/5 appeared to 
be down-regulated in only the DHA treated colon cancer cells. It has been implicated that 
the absence of BMP signaling may allow for the progression of cancer progression, 
specifically in many colorectal cancer cells.
13
 Although the BMP signaling is primarily 
known for inducing bone and cartilage growth, it has not been very well studied in cancer 
cells.
14
 In response to DHA treatment, which reduces cancer cell growth and 
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proliferation, the BMP signaling appeared to be suppressed. Overall, this is in contrast to 
its effect on promoting the progression of cancer according to the findings of the Kodach 
et. al paper.
13
 Several factors may contribute to this contradicting finding including the 
type of cancer cells being studied and the conditions by which the cells were growing. In 
general, different cancer cell lines can express and activate proteins in different ways and 
in many combinations so it is often difficult to definitively state what one mechanism is 
applicable to all cancer cells. 
Although both TGF-ß and BMP receptors signal through different SMADs in the 
SMAD pathway, SMAD4, which is the protein of intersection for both pathways, follows 
fatty acid treatment response as the upstream signaling pSMAD2 induced by TGF-ß 
signaling. Although other SMAD proteins and the TGF-ß and BMP receptor need to be 
analyzed, a conclusion could be made that intracellular TGF-ß/SMAD signaling may take 
precedence over the BMP/SMAD pathway in inducing the gene activation by 
downstream signaling of SMAD4. Again, the experiments need to be replicated and 
possibly be expanded to other colorectal cell lines. 
Even though this project was initially focused on the TGF-ß/SMAD signaling 
pathway, the project had expanded to looking at the SMAD pathway induced by BMP 
signaling. Even though both TGF-ß and BMP signal through different a different set of 
SMAD proteins and intersect at SMAD4, both pathways clearly had a response to DHA 
treatment. As a future direction, the TGF-ß and BMP receptors, along with other SMAD 
proteins (SMAD6, SMAD7, and SMAD3) and their activation states, should be examined 
in response to fatty acid treatment. SMAD6 and SMAD7 are antagonistic or inhibitory 
SMADs that prevent the dissociation of R-SMAD from the receptors, whereas SMAD3 
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associates with SMAD2 to form the R-SMAD complex.
8
 While SMAD proteins appear 
to be affected in response to DHA treatment, determining a mechanism on why this 
occurs is a potential direction to look into. It is likely that DHA may be incorporated into 
the lipid membrane, thereby disrupting interactions and activation signaling that would 
normally occur in the membrane of cancer cells. Overall, the findings of this project 
appear significant and merits further depth in understanding how the SMAD pathway is 
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